TG Therapeutics Inc (TGTX)

Working capital turnover

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Revenue (ttm)	US$ in thousands	262,359	340,582	280,254	222,343	180,883	18,875	6,331	2,784	5,025	6,961	7,912	6,689	4,406	2,414	907	152	152	152	152	152
Total current assets	US$ in thousands	574,069	389,150	360,581	317,943	319,114	208,574	184,783	168,274	182,922	202,560	242,216	330,965	371,779	455,068	535,013	611,740	260,335	280,938	88,016	149,151
Total current liabilities	US$ in thousands	125,114	108,664	99,684	53,720	57,678	72,667	63,076	53,201	36,447	43,326	54,656	65,384	87,655	87,551	92,494	87,554	77,670	67,537	63,118	84,449
Working capital turnover		0.58	1.21	1.07	0.84	0.69	0.14	0.05	0.02	0.03	0.04	0.04	0.03	0.02	0.01	0.00	0.00	0.00	0.00	0.01	0.00

September 30, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $262,359K ÷ ($574,069K – $125,114K)
= 0.58

The working capital turnover ratio measures how efficiently a company is using its working capital to generate revenue. A higher ratio indicates better efficiency in utilizing its current assets and liabilities.

In the case of TG Therapeutics Inc, the working capital turnover has shown fluctuations over the past few quarters. From the data provided, we see that the ratio has ranged from 0.00 to 1.21. This indicates varying levels of efficiency in managing working capital during different periods.

The ratio was particularly low in the earlier quarters, with values below 0.10. This suggests that the company may have had challenges in effectively utilizing its working capital to generate revenue during those periods.

However, there has been an improvement in recent quarters, with the ratio gradually increasing to 1.21 in the most recent quarter. This indicates a better utilization of working capital to generate revenue, which is a positive sign for the company's operational efficiency.

It is important for TG Therapeutics Inc to continue monitoring and improving its working capital turnover ratio to ensure optimal utilization of its resources and to support sustainable growth in the future.